James Sapirstein, CEO of AzurRx BioPharma, Inc. talks about AZRX’s products and therapies.


See the full episode at: https://newtothestreet.com/new-to-the-street-may-16-american-premium-water-winners-inc-innerscope-hearing-technologies-zk-international-azurrx-biopharma-simplicity-esports-and-gaming-paypolitan-petprodu

James Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc. (NASDAQ: AZRX), talks about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.